Ya. Luqmani et al., EXPRESSION OF FGFR2 BEK AND K-SAM MESSENGER-RNA VARIANTS IN NORMAL AND MALIGNANT HUMAN BREAST, European journal of cancer, 32A(3), 1996, pp. 518-524
The expression of mRNA encoding alternative forms of fibroblast growth
factor receptor 2 (FGFR2) differing in the carboxy terminal half of t
heir third immunoglobulin-like domain, was investigated in 77 human br
east cancer tissues, 12 non-malignant breast biopsies and 29 cell line
s, using a reverse transcriptase (RT) polymerase chain reaction (PCR)
method. RNA from the two tissue groups yielded PCR product correspondi
ng to both the BEK and the K-SAM form; amounts normalised to glycerald
ehyde phosphate dehydrogenase product were similar in both groups. The
level of either variant or of the total FGFR2 product was essentially
unrelated to prognosis or clinical status except that patients with a
dvanced clinical T staging had a higher proportion of BEK to K-SAM (P
= 0.01). RNA from 1/2 normal breast derived and 8/10 breast cancer cel
l lines expressed exclusively or predominantly the K-SAM form; 2/10 ha
d significant amounts of both BEK and K-SAM mRNA. Of 12 other epitheli
al lines, seven expressed mainly K-SAM mRNA, four expressed BEK and on
e was negative. Of five non-epithelial lines, one was negative, two ex
pressed only BEK mRNA and two had significant amounts of both variants
. We conclude that tissue levels of FGFR2 mRNA are unaltered in breast
cancer extracts and that the splicing mechanism for this exon selecti
on appears not to be significantly disrupted.